Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist. Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was approved for medical use in the United States in October 2019. In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.
Property | Value |
---|---|
dbo:abstract |
|
dbo:alternativeName |
|
dbo:casNumber |
|
dbo:chEMBL |
|
dbo:drugbank |
|
dbo:fdaUniiCode |
|
dbo:kegg |
|
dbo:medlinePlus |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageExternalLink | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:atcPrefix |
|
dbp:atcSuffix |
|
dbp:c |
|
dbp:casNumber |
|
dbp:chembl |
|
dbp:chemspiderid |
|
dbp:class |
|
dbp:dailymedid |
|
dbp:drugbank |
|
dbp:h |
|
dbp:iupacName |
|
dbp:kegg |
|
dbp:legalAu |
|
dbp:legalCa |
|
dbp:legalEu |
|
dbp:legalUs |
|
dbp:medlineplus |
|
dbp:n |
|
dbp:o |
|
dbp:pregnancyAu |
|
dbp:pregnancyCategory |
|
dbp:pubchem |
|
dbp:routesOfAdministration | |
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:synonyms |
|
dbp:tradename |
|
dbp:unii |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |